| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FLK2; STK1; CD135; FLK-2 |
| Entrez GeneID | 2322 |
| clone | 7B7C3 |
| WB Predicted band size | 130kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FLT3 (AA: 930-991) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与FLT3抗体相关的代表性文献摘要：
1. **《FLT3-targeted therapeutics for acute myeloid leukemia》**
- 作者：Levis, M.
- 摘要：综述FLT3突变在AML中的临床意义，讨论FLT3抑制剂(如Quizartinib)及单克隆抗体的开发进展，强调其克服耐药性和联合疗法的潜力。
2. **《A bispecific antibody targeting CD3 and FLT3 effectively eliminates AML blasts》**
- 作者：Reusch, U. et al.
- 摘要：报道一种双特异性抗体(CD3/FLT3)通过激活T细胞靶向FLT3阳性AML细胞，临床前研究显示显著抑制肿瘤生长并延长小鼠生存期。
3. **《Structural basis of FLT3 receptor recognition by therapeutic antibodies》**
- 作者：Carrol, J. & Smith, B.D.
- 摘要：解析FLT3受体与单克隆抗体的复合物晶体结构，揭示关键抗原表位，为优化抗体亲和力和特异性提供分子基础。
4. **《Antibody-drug conjugate targeting FLT3 demonstrates efficacy in AML xenograft models》**
- 作者：Zhao, H. et al.
- 摘要：开发一种FLT3抗体偶联药物(ADC)，在AML异种移植模型中显示高效杀伤FLT3-ITD突变细胞，且毒性可控，支持进一步临床转化。
FLT3 (FMS-like tyrosine kinase 3) is a class III receptor tyrosine kinase critical for hematopoiesis, particularly in the survival, proliferation, and differentiation of hematopoietic stem and progenitor cells. Aberrant FLT3 signaling, often due to mutations like internal tandem duplications (FLT3-ITD) or tyrosine kinase domain (FLT3-TKD) mutations, is implicated in acute myeloid leukemia (AML). These mutations drive constitutive activation of FLT3. promoting leukemogenesis and poor prognosis.
FLT3 antibodies are essential tools in research and diagnostics. They detect FLT3 expression and mutation status in AML patients via techniques like flow cytometry, immunohistochemistry, or Western blot. Clinically, therapeutic FLT3 inhibitors (e.g., midostaurin, gilteritinib) are small-molecule tyrosine kinase inhibitors (TKIs), but FLT3-targeting monoclonal antibodies (mAbs) are emerging as investigational therapies. These mAbs aim to block ligand binding or induce antibody-dependent cellular cytotoxicity (ADCC) against FLT3-expressing leukemia cells.
Current challenges include overcoming resistance to FLT3-targeted therapies and improving specificity. Combination strategies with chemotherapy or other targeted agents are under investigation. FLT3 antibodies also aid in monitoring minimal residual disease (MRD) and predicting therapeutic responses. Despite progress, further research is needed to optimize antibody-based approaches for AML treatment and biomarker-driven precision medicine.
×
